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Despite the fact that there have been significant developments in anti-cancer technology, ovarian cancer still remains one of the leading causes of gynecological cancer deaths in the United States. To contribute towards novel approaches with minimal toxicity in treatment of ovarian cancer we proposed the present work, where we are integrating the field of nanotechnology with ovarian cancer cell's unique property of overexpressing folic acid receptor alpha (FR-α) to specifically target ovarian cancer. A cerium oxide nanoparticle, called Nanoceria (NCe), that has the ability to act as an anti-oxidant in similar capacity as biological anti-oxidants was selected. NCe in our hands exhibited efficacy in inhibiting ovarian tumor growth in vivo. Taking advantage of the nanotechnology, NCe was conjugated with molecules of folic acid to specifically target ovarian tumors as they are known to over-express folate receptor. This would result in specific killing of ovarian cells by NCe while minimizing toxicity to normal tissue. Dr Seal's laboratory (UCF) was able to successfully conjugate NCe to folic acid to prepare folic acid tagged Nanoceria called FANCe. FA-NCe was tested in vitro and was observed to have higher anti-growth activity against ovarian cancer cells. This indicates that when given in animals, it maybe more potent in inhibiting ovarian tumor growth. 
INTRODUCTION
Despite the fact that there have been significant developments in anti-cancer technology, such as chemotherapy, vaccines and hormone therapy, ovarian cancer, ovarian cancer still remains one of the leading cause of gynecological cancer deaths in the United States. The current standard therapy of surgical removal followed by chemotherapy results in overall tumor reduction with survival rate less than 50%. Chemotherapy regimens for patients with ovarian cancer include cisplatin and paclitaxel for which most of the patients develop resistance and as side effect have severe toxicity to normal cells. Clearly, other novel approaches with minimal toxicity are urgently needed which may specifically target ovarian cancer cells with minimal or no effects on normal cells.
To join in this effort we proposed the present work, where we planned to integrate the field of nanotechnology with ovarian cancer cell's unique property of over-expressing folic acid receptor alpha (FR-a) specifically target ovarian cancer.
Our experimental nanoparticle is Nanoceria (NCe), a cerium oxide nanoparticle. Nanotechnology-based tools and techniques are rapidly emerging in the fields of medical imaging and targeted drug delivery. Cerium oxide is a rare-earth oxide that is found in the lanthanide series of the periodic table. Nanocrystalline cerium oxide (nanoceria) exhibits a blue shift in the ultraviolet absorption spectrum, the shifting and broadening of Raman allowed modes and lattice expansion as compared to bulk cerium oxide indicating its unique properties. Nanoceria has emerged as a fascinating and lucrative material in biomedical science due to its unique ability to switch oxidation states between (III) and (IV) depending upon the environment. The ability to switch between mixed oxidation states of nanoceria is comparable to biological antioxidants. This imparts nanoceria with a very important biological property of radical scavenging which can be tuned based upon the retention of oxygen vacancies (defects) and concentration of Ce3+ species in nanoceria (1). NCe synthesized in Dr. Seal's laboratory has been tailored to retain mixed valence states (3+ and 4+) with the size in the range of 3-5nm. The reversibility of oxidation state is the key property in making NCe a potent antioxidant, thereby eliminating the need for repeated dosage (2) . When generated intracellularly as a consequence of normal metabolism or pathological states, free radicals can strip electrons from cellular macromolecules and render them dysfunctional. Previous studies have demonstrated that cerium oxide nano-particles possess excellent antioxidant properties and act as potent, regenerative free radical scavengers in biological systems (1-3). These regenerative antioxidant properties are due, in part, to the valence structure of the cerium atom combined with inherent defects in the crystal lattice structure, which are magnified at the nano-scale.
Our proposal was based on our preliminary findings (presently in communication with Plos One), where we demonstrated that NCe by itself had the ability to abate ovarian tumor growth in an in an in vivo nude mouse model implanted with intraperitoneal A2780 human ovarian cancer cells. In the present work we had proposed to conjugate NCe to folic acid in order to specifically target ovarian cancer cells, which over-express FR-α. Folate receptor-α (FR-α) is a folate-binding protein overexpressed in ovarian and several other epithelial malignancies that has been used as a target for imaging and therapeutic strategies. Folate or folic acid, that binds to FR-α is an essential vitamin and critical metabolite needed for the biosynthesis of amino acids, DNA, RNA and methylation reactions. Folic acid is an of importance especially for one-carbon transfer processes mediated by enzyme systems involved in DNA synthesis (4) . Increased expression of FR-α has been described in various tumor tissues, including ovarian, endometrial and breast cancer (5) . While the function of FR-α in cancer is not fully understood, since, folates are critical metabolites for nucleotide synthesis and methylation reactions, its overexpression might confer a tumor growth advantage by increasing folate availability to cancer cells (5) . Over 90% of nonmucinous ovarian cancers over-express FR-α (6).
Several strategies have been employed to target the folate receptor including the use of anti -FR-α antibodies or folic acid (FA) conjugates.
We had hypothesize that targeted delivery of folic acid (FA) conjugated nanoceria (NCe) will specifically target the ovarian cancer cell and further modification of folic acid conjugated nanoceria to cisplatin will result in specific targeting and delivery of cisplatin resulting in exclusive elimination of ovarian tumor cells in vivo. Due to the change of institute for the PI and time required to set a new lab from scratch, the work is currently behind the proposed SOW. In the present report we present the ability of Dr Seal's laboratory to successfully conjugate folic acid with NCe and some in vitro data demonstrating its efficacy against ovarian cancer cells.
We and will be working at out complete capacity to make up for the lost time.
BODY OF WORK TIME LINE OF EVENTS:
The grant was awarded to the PI, Ramandeep Rattan, while at Mayo Clinic, Rochester MN 55905 in 2010. By the time all the paperwork involved was completed the PI had moved to Henry Ford Health System (HFHS), Detroit, MI 48202 in September of 2011. The grant was transferred to HFHS and all the paperwork and other conditions required had to be redone.
1. PI joined HFHS on September 1, 2011. 
DATA:
1. Synthesis and characterization of cerium oxide nanoparticles: Cerium oxide nanoparticles used in this study contain individual crystallites of 3-5nm that are loosely agglomerated to 15-25nm. As the synthesis process is free from any organic surfactant the hard agglomeration of nanoparticles is controlled by tightly controlling the pH of the nanoparticles below 3.5 during synthesis to keep them in colloidal range. Figure 1 A and B shows the high resolution transmission electron micrographs (HRTEM) of NCe nanoparticles. It is evident from the image that nanoparticles are loosely agglomerated to about 15-25nm aggregates which could also be induced by the drying process. The hydrodynamic radius (37.8 nm ± 0.8) from the multimodal size distribution (volume %) analysis of DLS measurements agrees with the loose agglomerate size of the HRTEM analysis. High magnification image confirms the lattice planes of NCe in individual 3-5nm crystallites. UV-Visible spectroscopy was used to analyze the oxidation states of cerium oxide nanoparticles before and after aging treatment. Figure 1C shows the UV-Visible spectra from fresh and aged cerium oxide nanoparticles clearly indicating the predominance of Ce +3 oxidation state from the absorption peak at 252 nm as compared to absorption peak at 298 nm for Ce 4+ . Further confirmation on the oxidation states of nanoparticles was obtained from XPS analysis (Fig. 1D) . The XPS spectrum of cerium is very complex that contains multiple peaks from the spin orbit coupling of 3d orbitals (7) . Several peaks in the Ce3d region that have been ascribed to 3d 3/2 (899.5, 900.9, 903.5, 906.4 and 916.6) and 3d 5/2 (880.2, 882.1, 8885, 888.1 and 898) arising from multiple valence states of cerium. The spectrum from NCe shows a predominance of cerium in +3 oxidation state as depicted by the characteristic peaks at 880.2, 885.0, 899.5 and 903.5 eV.
Taken together the data from characterization of NCe is consistent with previous reports wherein cerium can be retained in trivalent oxidation by decreasing the size of the nanoparticles (1-3, 8) 2. NCe treatment inhibits production of ROS levels in A2780 cell line: Cerium oxide nanoparticles have been shown to act as free radical scavengers by inhibiting the production ofreactive oxygen species (ROS) (7, 9, 10) . Since, it is well established that ROS accumulation playsan important role in initiation and progression of tumorigenesis in human ovarian cancer (11, 12) , we examined the effect of NCe on ROS generation in ovarian cancer cell line A2780. A2780 cell line was treated with NCe (50-100 M) and post 48h of treatment, ROS generation was measured using DCFH2-DA dye followed by fluorescence reading. As shown in figure 1E , F, NCe treatment significantly inhibited ROS levels in A2780 cell line, suggesting that NCe treatment inhibits basal levels of oxidative stress in A2780 OvCa cell line. Cerium oxide nanoparticles were synthesized by using precipitation method and as described above (13) .
Synthesis and characterization of
Final nanoparticles were dried overnight under vacuum at 60-80°C.
Cerium oxide nanoparticles (CNPs) obtained by this method were then functionalized with amine (CO2-NH2) by using 3-aminopropyltrimethoxysilane as described elsewhere (14) . Folic acid were conjugated to the amine functionalized by using 1-ethyl-3- [3- dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide (Sulfo-NHS) coupling chemistry. Molar ratio of folic acid:CeO2-NH2:Sulfo-NHS-EDC was 1:1:2.2:11.2. Reaction was carried for 24hr and then washed in both DMSO and water to remove EDC, Sulfo-NHS and unbound folic acid. Finally, folic acid conjugated CeO2 (FA-NCe) were dried under vacuum at 40°C. CeO2-FA was then characterized by using high resolution transmission electron microscopy (HRTEM), X-ray diffraction (XRD) and dynamic light scattering (DLS). HRTEM images show the size of the CeO2-FA is ~10nm (Fig. 2A, B) . Hydrodynamic radii of CeO2 were found in approximately ~30nm nanometers with small percentage having 150nm agglomerated particles (Fig 2C) . The surface charge of the CeO2-FA has been also analyzed and found to be 25mV. XRD data confirm microcrystalline nature of the particles (Fig 2D) .
FA-NCe inhibits ovarian cancer proliferation in vitro.
Our previous data with NCe had shown no effect on proliferation of ovarian cancer cells. Therefore we wanted to determine if FA-NCe has the ability to affect growth on ovarian cancer cells in vitro. For this cisplatin sensitive A2780 and resistant C200 were plated in 96 well plates at 4x10 3 cells/well and treated in triplicates with various concentrations of NCe (10-100 μM). Cell viability was determined at 72hrs by MTT assay as described before (15) . As shown in figure 3, NCe treatment had no significant effect on the proliferation or survival of ovarian cancer cell lines both A2780 (Fig 3A) or C200 (Fig.  3B) . While FA-NCe showed significant inhibition in proliferation/cell death in both the cell lines (black bars). 
FA-NCe show higher efficacy that NCe in inhibiting ovarian cancer colony forming ability.
To confirm our previous result we also performed the colony formation assay as it considered a better assay to determine drug effect on cancer cells. For this, 2000 A2780 and C200 cells were plated in triplicates in 6-well plates and treated with indicated concentrations of NCe. The cells were allowed to form colonies for up to 2weeks and media was replaced every fourth day. Colonies were stained with MTT and counted as described before (15) . The clonogenic assay also showed similar results where NCe treatment showed no significant change, while FA-NCe significantly inhibited colony formation of both A2780 and C200 cell lines (Fig. 4; black bars) . 
CONCLUSION
Nanoceria conjugated with folic acid appears to have higher anti-tumor activity against cisplatin sensitive and resistant ovarian cancer cells in vitro. This indicates that when given in animals, it maybe more potent in inhibiting ovarian tumor growth, which agrees with our hypothesis.
